Weavr Health in the news
Weavr Health Named a “2022 Best Place to Work” by Built In
Weavr Health Named a “2022 Best Place to Work” by Built In CAMBRIDGE, Mass. – Jan. 5, 2022 – Weavr Health, a diagnostics company focused on revolutionizing diagnostic testing, was recognized on the Built In 2022 list of 50 Best Small Places to Work in Boston. “Over the past year, we have nearly tripled the size of our team and have made key clinical and regulatory hires as we focus on expanding applications and partnerships for our at-home blood collection and testing platform,” said Linh…
Bloomberg: If We Have Vaccines, Why Do We Still Need Testing?
Before vaccines became the core tool to fight Covid-19, it was testing. Now, with inoculations on the rise, demand for testing is declining, a development that led diagnostic giant Abbott Laboratories to slash its 2021 profit guidance. The pandemic is far from over, though, and testing will continue to be essential in the struggle to control outbreaks, identify emerging variants and allow…
Nightingale secures global scalability of its at-home solution by partnering with Weavr
Company Release Inside Information 29 June 2021 at 9:40 a.m. (Finnish Time) Nightingale Health Plc (“Nightingale”), and Weavr Health Corp. (“Weavr”, formerly Boston MicroFluidics, Inc.) have established a strategic partnership by expanding the existing distribution agreement between the parties with new commercial terms. The new commercial terms are effective as of today. Nightingale today also…
Weavr Health Submits EUA Request for Rapid, At-Home COVID-19 Antibody Test
FDA Emergency Use Authorization of Silk COVID-19 Rapid Antibody Test would enable at-home testing for COVID-19 IgG and IgM antibodies with results in as few as 10 minutes CAMBRIDGE, Mass. – June 8, 2021 – Weavr Health (formerly Boston Microfluidics), a diagnostics company, has submitted a request to the U.S. Food and Drug Administration (FDA)…
How Weavr Health Can Enable Widespread Serologic Testing for COVID-19*
Serologic Testing has become an increasing area of focus for government officials globally.
As studies mount that show large percentages of people (15-25%) who have been exposed to SARS-Cov-2 are asymptomatic throughout the course of the disease, serologic testing has received a renewed focus.
Boston Microfluidics Appoints Linh Hoang, MD, PhD as CEO
Boston Microfluidics (BMF), a developer of simple, intuitive blood collection devices, today announced that it has appointed Linh Hoang, MD, PhD, as its new Chief Executive Officer. In his new role, Dr. Hoang will oversee the company’s strategic growth and commercialization efforts of BMF’s products and services.
Boston Microfluidics Raises $17.5M in Series A Funding Round
Boston Microfluidics (BMF), a developer of simple, intuitive blood collection devices, today announced it has raised $17.5 million in new funding. The Series A round was led by venture capital firm Anzu Partners and included leading global life sciences company (LabCorp Holdings).